HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk



The Endocrinology Network® Osteoporosis clinical resource center is our hub for the latest in bone health and management of fracture risk. With a fracture causing significant increases in risk of mortality, management of osteoporosis represents a crucial aspect of care. This page will offer the latest information related to FDA approvals, new studies, and guideline updates pertaining to diagnosis and management of osteoporosis.

Abaloparatide Receives FDA Approval for Osteoporosis in Men

December 20, 2022

Announced by Radius Health on December 20, the US FDA approval for abaloparatide (Tymlos) indicates the agent as a treatment to increase bone density in men with osteoporosis at high risk of fracture or in patients who have failed or are intolerant to other available osteoporosis therapy.

Study Compares Fracture Risk Among Antidiabetes Medication Regimens

June 27, 2022

An analysis of real-world data from more than 6500 patients suggests insulin users had a greater risk of fracture than patients using metformin, but this became attenuated among patients using a combination of insulin and metformin.

Parathyroidectomy Can Reduce Adverse Outcomes Risk in Primary Hyperparathyroidism

June 20, 2022

Data from Sweden national registers provide insight into the increased risk of adverse outcomes, including fracture, cardiovascular events, and mortality risk, associated with primary hyperparathyroidism as well as the apparent reductions in risk achieved by undergoing parathyroidectomy.

Endocrine Month in Review: April 2022

April 23, 2022

Our endocrine month in review spotlights the most popular articles from the past month. This month's top articles include a multipart video series, new diabetes, information on osteoporosis, and more!